Ken Griffin Rockwell Medical, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$1.45 - $1.92 $20,735 - $27,456	-14,300 Reduced 88.82%	1,800 $3,000
Q1 2024 May 15, 2024	BUY	$1.23 - $1.86 $12,423 - $18,786	10,100 Added 168.33%	16,100 $26,000
Q4 2023 Feb 14, 2024	SELL	$1.58 - $2.44 $52,298 - $80,764	-33,100 Reduced 84.65%	6,000 $11,000
Q3 2023 Nov 14, 2023	BUY	$1.83 - $6.19 $42,090 - $142,370	23,000 Added 142.86%	39,100 $81,000
Q2 2023 Aug 14, 2023	BUY	$1.8 - $5.46 $24,660 - $74,802	13,700 Added 570.83%	16,100 $87,000
Q1 2023 May 15, 2023	BUY	$1.03 - $2.62 $2,163 - $5,502	2,100 Added 700.0%	2,400 $4,000
Q4 2022 Feb 14, 2023	BUY	$0.84 - $1.39 $252 - $416	300 New	300 $0

6.35M

11K

32.1K

Ticker RMTI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 10,675,200
Market Cap $44.1M
Description
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iro...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.